Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Condition(s):Metastatic Melanoma; Metastatic Renal CancerLast Updated:October 28, 2015Terminated
Hide Studies Not Open or Pending
Condition(s):Metastatic Melanoma; Metastatic Renal CancerLast Updated:October 28, 2015Terminated
Condition(s):Renal Cancer MetastaticLast Updated:March 15, 2022Unknown status
Condition(s):Renal Cancer; Kidney CancerLast Updated:April 9, 2019Terminated
Condition(s):Renal Cell CancerLast Updated:August 29, 2016Completed
Condition(s):Renal Cell CarcinomaLast Updated:January 25, 2024Active, not recruiting
Condition(s):Carcinoma, Renal CellLast Updated:December 23, 2014Completed
Condition(s):Metastatic Kidney CancerLast Updated:July 23, 2019Not yet recruiting
Condition(s):Kidney NeoplasmsLast Updated:January 29, 2020Completed
Condition(s):Metastatic Clear Cell Renal CarcinomaLast Updated:June 24, 2014Terminated
Condition(s):Kidney Neoplasms; Neoplasm MetastasisLast Updated:March 4, 2008Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.